NanoString Technologies (NSTG) – Analysts’ Weekly Ratings Changes

Share on StockTwits

A number of firms have modified their ratings and price targets on shares of NanoString Technologies (NASDAQ: NSTG) recently:

  • 12/3/2019 – NanoString Technologies was upgraded by analysts at Zacks Investment Research from a “sell” rating to a “hold” rating. According to Zacks, “NanoString Technologies, Inc. is engaged in the development, manufacture and sale of life science tools. It provides nCounter Analysis System which supports research and development of clinical applications from basic discovery to the development of future molecular diagnostic tests on a single platform. The company also offers nSolver Analysis software, gene expression panels, miRNA expression assay kits, cancer copy number variation panels, nCounter leukemia fusion gene expression assay kits and human karyotype panels, custom CodeSets and master kits that are ancillary reagents, cartridges, tips and reagent plates to setup and process samples in its instruments. It markets its systems and related consumables to researchers in academic, government and biopharmaceutical laboratories primarily in North America, Europe, the Middle East and the Asia Pacific. NanoString Technologies, Inc. is headquartered in Seattle, Washington. “
  • 11/25/2019 – NanoString Technologies was upgraded by analysts at BidaskClub from a “hold” rating to a “buy” rating.
  • 11/21/2019 – NanoString Technologies was upgraded by analysts at Zacks Investment Research from a “sell” rating to a “hold” rating. According to Zacks, “NanoString Technologies, Inc. is engaged in the development, manufacture and sale of life science tools. It provides nCounter Analysis System which supports research and development of clinical applications from basic discovery to the development of future molecular diagnostic tests on a single platform. The company also offers nSolver Analysis software, gene expression panels, miRNA expression assay kits, cancer copy number variation panels, nCounter leukemia fusion gene expression assay kits and human karyotype panels, custom CodeSets and master kits that are ancillary reagents, cartridges, tips and reagent plates to setup and process samples in its instruments. It markets its systems and related consumables to researchers in academic, government and biopharmaceutical laboratories primarily in North America, Europe, the Middle East and the Asia Pacific. NanoString Technologies, Inc. is headquartered in Seattle, Washington. “
  • 11/15/2019 – NanoString Technologies was downgraded by analysts at Zacks Investment Research from a “hold” rating to a “sell” rating. According to Zacks, “NanoString Technologies, Inc. is engaged in the development, manufacture and sale of life science tools. It provides nCounter Analysis System which supports research and development of clinical applications from basic discovery to the development of future molecular diagnostic tests on a single platform. The company also offers nSolver Analysis software, gene expression panels, miRNA expression assay kits, cancer copy number variation panels, nCounter leukemia fusion gene expression assay kits and human karyotype panels, custom CodeSets and master kits that are ancillary reagents, cartridges, tips and reagent plates to setup and process samples in its instruments. It markets its systems and related consumables to researchers in academic, government and biopharmaceutical laboratories primarily in North America, Europe, the Middle East and the Asia Pacific. NanoString Technologies, Inc. is headquartered in Seattle, Washington. “
  • 11/14/2019 – NanoString Technologies is now covered by analysts at Stifel Nicolaus. They set a “buy” rating and a $28.00 price target on the stock.
  • 11/9/2019 – NanoString Technologies was downgraded by analysts at Zacks Investment Research from a “hold” rating to a “sell” rating. According to Zacks, “NanoString Technologies, Inc. is engaged in the development, manufacture and sale of life science tools. It provides nCounter Analysis System which supports research and development of clinical applications from basic discovery to the development of future molecular diagnostic tests on a single platform. The company also offers nSolver Analysis software, gene expression panels, miRNA expression assay kits, cancer copy number variation panels, nCounter leukemia fusion gene expression assay kits and human karyotype panels, custom CodeSets and master kits that are ancillary reagents, cartridges, tips and reagent plates to setup and process samples in its instruments. It markets its systems and related consumables to researchers in academic, government and biopharmaceutical laboratories primarily in North America, Europe, the Middle East and the Asia Pacific. NanoString Technologies, Inc. is headquartered in Seattle, Washington. “
  • 11/1/2019 – NanoString Technologies was upgraded by analysts at ValuEngine from a “hold” rating to a “buy” rating.
  • 10/29/2019 – NanoString Technologies was upgraded by analysts at BidaskClub from a “sell” rating to a “hold” rating.
  • 10/24/2019 – NanoString Technologies was upgraded by analysts at Zacks Investment Research from a “hold” rating to a “buy” rating. They now have a $24.00 price target on the stock. According to Zacks, “NanoString Technologies, Inc. is engaged in the development, manufacture and sale of life science tools. It provides nCounter Analysis System which supports research and development of clinical applications from basic discovery to the development of future molecular diagnostic tests on a single platform. The company also offers nSolver Analysis software, gene expression panels, miRNA expression assay kits, cancer copy number variation panels, nCounter leukemia fusion gene expression assay kits and human karyotype panels, custom CodeSets and master kits that are ancillary reagents, cartridges, tips and reagent plates to setup and process samples in its instruments. It markets its systems and related consumables to researchers in academic, government and biopharmaceutical laboratories primarily in North America, Europe, the Middle East and the Asia Pacific. NanoString Technologies, Inc. is headquartered in Seattle, Washington. “

Shares of NSTG stock traded up $0.06 during mid-day trading on Friday, reaching $26.40. The stock had a trading volume of 18,221 shares, compared to its average volume of 493,115. The firm has a market capitalization of $953.49 million, a PE ratio of -9.50 and a beta of 1.16. The stock’s 50-day moving average price is $23.94 and its two-hundred day moving average price is $25.66. The company has a current ratio of 4.73, a quick ratio of 4.23 and a debt-to-equity ratio of 1.51. NanoString Technologies Inc has a 52-week low of $13.26 and a 52-week high of $34.78.

NanoString Technologies (NASDAQ:NSTG) last issued its quarterly earnings data on Monday, November 4th. The biotechnology company reported ($0.64) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.54) by ($0.10). NanoString Technologies had a negative return on equity of 118.32% and a negative net margin of 72.30%. The business had revenue of $30.60 million during the quarter, compared to the consensus estimate of $28.05 million. On average, equities research analysts forecast that NanoString Technologies Inc will post -2.48 earnings per share for the current year.

In other NanoString Technologies news, Director William Young sold 24,125 shares of the firm’s stock in a transaction dated Friday, November 22nd. The shares were sold at an average price of $24.86, for a total value of $599,747.50. Following the completion of the sale, the director now directly owns 54,125 shares in the company, valued at $1,345,547.50. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Director Charles P. Waite, Jr. sold 1,707 shares of NanoString Technologies stock in a transaction that occurred on Friday, September 13th. The shares were sold at an average price of $21.75, for a total value of $37,127.25. The disclosure for this sale can be found here. Insiders sold 64,197 shares of company stock valued at $1,570,126 in the last ninety days. 5.10% of the stock is currently owned by insiders.

Several hedge funds have recently bought and sold shares of the business. James Investment Research Inc. bought a new stake in shares of NanoString Technologies during the second quarter valued at approximately $25,000. Zurcher Kantonalbank Zurich Cantonalbank purchased a new stake in shares of NanoString Technologies in the 2nd quarter worth about $75,000. Mizuho Securities Co. Ltd. bought a new position in shares of NanoString Technologies in the 2nd quarter worth about $91,000. Truvestments Capital LLC increased its stake in shares of NanoString Technologies by 32.2% in the 3rd quarter. Truvestments Capital LLC now owns 3,240 shares of the biotechnology company’s stock worth $70,000 after acquiring an additional 790 shares in the last quarter. Finally, Bank of Montreal Can increased its stake in shares of NanoString Technologies by 104.1% in the 2nd quarter. Bank of Montreal Can now owns 5,396 shares of the biotechnology company’s stock worth $164,000 after acquiring an additional 2,752 shares in the last quarter.

NanoString Technologies, Inc provides life science tools for translational research and molecular diagnostic products worldwide. The company offers nCounter Analysis System, an automated, multi-application, digital detection, and counting system. It provides nCounter MAX and FLEX systems that include Prep Station, an automated liquid handling component that processes and prepares samples for data collection; and nCounter Digital Analyzer, which collects data from samples by taking images of the immobilized fluorescent reporters in the sample cartridge and processing the data into output files.

Read More: Dividend Stocks – Are They Right For You?

Receive News & Ratings for NanoString Technologies Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NanoString Technologies Inc and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Yu Darvish Receives Cortisone Shot for Elbow Impingement
Yu Darvish Receives Cortisone Shot for Elbow Impingement
Red Sox and Brandon Phillips Agree to Minor League Deal
Red Sox and Brandon Phillips Agree to Minor League Deal
Chris Sale Proves He is 2018 AL Cy Young Candidate
Chris Sale Proves He is 2018 AL Cy Young Candidate
Strong Results by Clint Frazier Could Keep Him with Yankees
Strong Results by Clint Frazier Could Keep Him with Yankees
Giants Closer Breaks Hand Punching Door Following Poor Outing
Giants Closer Breaks Hand Punching Door Following Poor Outing
Evan Longoria Out Six to Eight Weeks With Broken Hand
Evan Longoria Out Six to Eight Weeks With Broken Hand


 
© 2006-2020 BBNS.